Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno

被引：18

作者：

Brazel, Danielle ^{[1
]}

Ou, Sai-Hong Ignatius ^{[1
,2
]}

Nagasaka, Misako ^{[1
,2
,3
,4
]}

机构：

[1] Univ Calif Irvine Sch Med, Dept Med, Orange, CA USA

[2] Chao Family Comprehens Canc Ctr, Orange, CA USA

[3] St Marianna Univ Sch Med, Kawasaki, Japan

[4] Univ Calif Irvine Sch Med, Dept Med, 101 City Dr, Orange, CA 92617 USA

来源：

LUNG CANCER-TARGETS AND THERAPY | 2023年 / 14卷

关键词：

tiragolumab; TIGIT; immunotherapy; small cell lung cancer; CELL LUNG-CANCER; PVR;

D O I：

10.2147/LCTT.S379389

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Small cell lung cancer (SCLC) is characterized by rapid progression and poor prognosis. Although the phase II CITYSCAPE-02 trial found objective response rate (ORR) and progression-free survival (PFS) of non-small cell lung cancer (NSCLC) patients improved when tiragolumab was added to atezolizumab and chemotherapy, the phase III SKYSCRAPER-02 failed to find PFS or OS benefit in patients with SCLC. Atezolizumab was the first immunotherapy to show survival benefit in extensive SCLC based on the phase III IMpower133 study. Given that immunotherapy has become the standard of care for SCLC patients, further research is needed into ways to augment the immune system to better treat these patients.

引用

页码：1 / 9

页数：9

共 30 条

[1]

[Anonymous], 2022, Genentech reports interim results for Phase III SKYSCRAPER-01 study in PD-L1-high metastatic non-small cell lung cancer

[2]

[Anonymous], 2022, GENENTECH PROVIDES U

[3] Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors [J].

Bendell, Johanna C. ;

Bedard, Philippe ;

Bang, Yung-Jue ;

LoRusso, Patricia ;

Hodi, Stephen ;

Gordon, Michael ;

D'Angelo, Sandra ;

Desai, Jayesh ;

Garralda, Elena ;

Italiano, Antoine ;

Myung-Ju Ahn ;

Cervantes, Andres ;

Wainberg, Zev ;

Calvo, Emiliano ;

Gil-Martin, Marta ;

Martinez-Garcia, Maria ;

Bahleda, Rastilav ;

Cassier, Philippe ;

Delord, Jean-Pierre ;

Prawira, Amy ;

Melero, Ignacio ;

Emens, Leisha ;

Romano, Emanuela ;

Miller, Karen ;

Hsieh, Robert W. ;

Xue, Cloris ;

Morrissey, Kari ;

Twomey, Patrick ;

Gash, Kelly ;

Patil, Namrata S. ;

Grogan, Jane ;

Meng, Raymond ;

Cho, Byoung ;

Kim, Tae Won .

CANCER RESEARCH, 2020, 80 (16)

[4] A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC [J].

Boles, Kent S. ;

Vermi, William ;

Facchetti, Fabio ;

Fuchs, Anja ;

Wilson, Timothy J. ;

Diacovo, Thomas G. ;

Cella, Marina ;

Colonna, Marco .

EUROPEAN JOURNAL OF IMMUNOLOGY, 2009, 39 (03) :695-703

[5] Targeting PVR (CD155) and its receptors in anti-tumor therapy [J].

Brlic, Paola Kucan ;

Rovis, Tihana Lenac ;

Cinamon, Guy ;

Tsukerman, Pini ;

Mandelboim, Ofer ;

Jonjic, Stipan .

CELLULAR & MOLECULAR IMMUNOLOGY, 2019, 16 (01) :40-52

[6]

Caruso C, 2020, CANCER DISCOV, V10, P1086, DOI 10.1158/2159-8290.CD-NB2020-063

[7] Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study [J].

Cho, Byoung Chul ;

Abreu, Delvys Rodriguez ;

Hussein, Maen ;

Cobo, Manuel ;

Patel, Anjan J. ;

Secen, Nevena ;

Lee, Ki Hyeong ;

Massuti, Bartomeu ;

Hiret, Sandrine ;

Yang, James Chih Hsin ;

Barlesi, Fabrice ;

Lee, Dae Ho ;

Ares, Luis Paz ;

Hsieh, Robert W. ;

Patil, Namrata S. ;

Twomey, Patrick ;

Yang, Xiaoying ;

Meng, Raymond ;

Johnson, Melissa L. .

LANCET ONCOLOGY, 2022, 23 (06) :781-792

[8] Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities [J].

Gay, Carl M. ;

Stewart, C. Allison ;

Park, Elizabeth M. ;

Diao, Lixia ;

Groves, Sarah M. ;

Heeke, Simon ;

Nabet, Barzin Y. ;

Fujimoto, Junya ;

Solis, Luisa M. ;

Lu, Wei ;

Xi, Yuanxin ;

Cardnell, Robert J. ;

Wang, Qi ;

Fabbri, Giulia ;

Cargill, Kasey R. ;

Vokes, Natalie, I ;

Ramkumar, Kavya ;

Zhang, Bingnan ;

Della Corte, Carminia M. ;

Robson, Paul ;

Swisher, Stephen G. ;

Roth, Jack A. ;

Glisson, Bonnie S. ;

Shames, David S. ;

Wistuba, Ignacio I. ;

Wang, Jing ;

Quaranta, Vito ;

Minna, John ;

Heymach, John, V ;

Byers, Lauren Averett .

CANCER CELL, 2021, 39 (03) :346-+

[9] Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial [J].

Goldman, Jonathan W. ;

Dvorkin, Mikhail ;

Chen, Yuanbin ;

Reinmuth, Niels ;

Hotta, Katsuyuki ;

Trukhin, Dmytro ;

Statsenko, Galina ;

Hochmair, Maximilian J. ;

Ozguroglu, Mustafa ;

Ji, Jun Ho ;

Garassino, Marina Chiara ;

Voitko, Oleksandr ;

Poltoratskiy, Artem ;

Ponce, Santiago ;

Verderame, Francesco ;

Havel, Libor ;

Bondarenko, Igor ;

Kazarnowicz, Andrzej ;

Losonczy, Gyorgy ;

Conev, Nikolay V. ;

Armstrong, Jon ;

Byrne, Natalie ;

Thiyagarajah, Piruntha ;

Jiang, Haiyi ;

Paz-Ares, Luis .

LANCET ONCOLOGY, 2021, 22 (01) :51-65

[10] Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database [J].

Govindan, Ramaswamy ;

Page, Nathan ;

Morgensztern, Daniel ;

Read, William ;

Tierney, Ryan ;

Vlahiotis, Anna ;

Spitznagel, Edward L. ;

Piccirillo, Jay .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (28) :4539-4544

← 1 2 3 →